Emerging Safety Science / Nejlevnější knihy
Emerging Safety Science

Kód: 04578667

Emerging Safety Science

Autor Sally Robinson, Robert Pool, Robert Giffin, Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medic

In recent years, the costs of new drug development have skyrocketed. The average cost of developing a new approved drug is now estimated to be $1.3 billion (DiMasi and Grabowski, 2007). At the same time, each year fewer new molecu ... celý popis


Momentálně nedostupné

Informovat o naskladnění

Přidat mezi přání

Mohlo by se vám také líbit

Informovat o naskladnění knihy

Informovat o naskladnění knihy


Souhlas - Souhlasím se zasíláním obchodních sdělení a zpracováním osobních údajů k obchodním sdělením.

Zašleme vám zprávu jakmile knihu naskladníme

Zadejte do formuláře e-mailovou adresu a jakmile knihu naskladníme, zašleme vám o tom zprávu. Pohlídáme vše za vás.

Více informací o knize Emerging Safety Science

Anotace knihy

In recent years, the costs of new drug development have skyrocketed. The average cost of developing a new approved drug is now estimated to be $1.3 billion (DiMasi and Grabowski, 2007). At the same time, each year fewer new molecular entities (NMEs) are approved. DiMasi and Grabowski report that only 21.5 percent of the candidate drugs that enter phase I clinical testing actually make it to market. In 2007, just 17 novel drugs and 2 novel biologics were approved. In addition to the slowing rate of drug development and approval, recent years have seen a number of drugs withdrawn from the market for safety reasons. According to the Government Accountability Office (GAO), 10 drugs were withdrawn because of safety concerns between 2000 and March 2006 (GAO, 2006). Finding ways to select successful drug candidates earlier in development could save millions or even billions of dollars, reduce the costs of drugs on the market, and increase the number of new drugs with improved safety profiles that are available to patients. Emerging scientific knowledge and technologies hold the potential to enhance correct decision making for the advancement of candidate drugs. Identification of safety problems is a key reason that new drug development is stalled. Traditional methods for assessing a drug's safety prior to approval are limited in their ability to detect rare safety problems. Prior to receiving U.S. Food and Drug Administration (FDA) approval, a drug will have been tested in hundreds to thousands of patients. Generally, drugs cannot confidently be linked to safety problems until they have been tested in tens of thousands to hundreds of thousands of people. With current methods, it is unlikely that rare safety problems will be identified prior to approval. Emerging Safety Science: Workshop Summary summarizes the events and presentations of the workshop.

Parametry knihy

Zařazení knihy Knihy v angličtině Medicine Medicine: general issues Medical equipment & techniques

Oblíbené z jiného soudku



Osobní odběr Praha, Brno a 46611 dalších

Copyright ©2008-26 nejlevnejsi-knihy.cz Všechna práva vyhrazenaSoukromíCookies


Můj účet: Přihlásit se
Všechny knihy světa na jednom místě. Navíc za skvělé ceny.

Nákupní košík ( prázdný )

Vyzvednutí v Balikovně a PPL
boxech
zdarma nad 1 499 Kč.

Nacházíte se: